Common use of Payment Models Clause in Contracts

Payment Models. Model 1: USD [***] due and payable thirty (30) days after the signing of this Agreement; plus • USD [***] due and payable after the date of FDA notification if the initial NDA results in a final FDA approval of the Product for the indication HTG upon the later of (i) thirty (30) days after such notification, and (ii) the transfer of the Registration for the Product to RELIANT; or • USD [***] due and payable thirty (30) days after the date of FDA notification if the initial NDA results in an Approvable Letter (unless RELIANT shall not have provided a notice to PRONOVA under Section 3.3(a)), plus USD [***] due and payable upon the later of (i) thirty (30) days after the date of FDA notification of final FDA approval of the Product for the indication HTG, and (ii) the transfer of the Registration for the Product to RELIANT. Model 2: USD [***] due and payable thirty (30) days after signing of this Agreement; plus • USD [***] due and payable after the date of FDA notification if the initial NDA results in a final FDA approval of the Product for the indication HTG upon the later of (i) thirty (30) days after such notification, and (ii) the transfer of the Registration for the Product to RELIANT; or • USD [***] due and payable thirty (30) days after the date of FDA notification if the initial NDA results in an Approvable Letter from FDA (unless RELIANT shall not have provided a notice to PRONOVA under Section 3.3(a)), plus USD [***] due and payable upon the later of (i) thirty (30) days after the date of FDA notification of final FDA approval of the Product for the indication HTG, and (ii) the transfer of the Registration for the Product to RELIANT. RELIANT’s obligation to make any of the foregoing “final FDA approval” payments shall be conditioned upon RELIANT’s having received access to validated API to create finished encapsulated Product for sale in the Territory. [***]: Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. Schedule 5.2

Payment Models. Model 1: USD [***] due and payable thirty (30) days after the signing of this Agreement; plus • USD [***] due and payable after the date of FDA notification if the initial NDA results in a final FDA approval of the Product for the indication HTG upon the later of (i) thirty (30) days after such notification, and (ii) the transfer of the Registration for the Product to RELIANT; or • USD [***] due and payable thirty (30) days after the date of FDA notification if the initial NDA results in an Approvable Letter (unless RELIANT shall not have provided a notice to PRONOVA under Section 3.3(a)), plus USD [***] due and payable upon the later of (i) thirty (30) days after the date of FDA notification of final FDA approval of the Product for the indication HTG, and (ii) the transfer of the Registration for the Product to RELIANT. Model 2: USD [***] due and payable thirty (30) days after signing of this Agreement; plus • USD [***] due and payable after the date of FDA notification if the initial NDA results in a final FDA approval of the Product for the indication HTG upon the later of (i) thirty (30) days after such notification, and (ii) the transfer of the Registration for the Product to RELIANT; or • USD [***] due and payable thirty (30) days after the date of FDA notification if the initial NDA results in an Approvable Letter from FDA (unless RELIANT shall not have provided a notice to PRONOVA under Section 3.3(a)), plus USD [***] due and payable upon the later of (i) thirty (30) days after the date of FDA notification of final FDA approval of the Product for the indication HTG, and (ii) the transfer of the Registration for the Product to RELIANT. RELIANT’s obligation to make any of the foregoing “final FDA approval” payments shall be conditioned upon RELIANT’s having received access to validated API to create finished encapsulated Product for sale in the Territory. [***]: Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. Schedule 5.25.2 Forecasting, Ordering and Delivery procedures (examples) Schedule 5.12(b) Territories in which PRONOVA Currently has Licensing or Supply Agreements for API (or Active Pharmaceutical Ingredients Similar to API) Europe & “former Soviet Union” Germany Austria United Kingdom Ireland Belgium Netherlands Luxembourg Switzerland Greece Spain Portugal France Italy X. Xxxxxx Vatican City Norway Sweden Finland Denmark Iceland Estonia Latvia Lithuania Poland Czech Republic Slovakia Hungary Romania Bulgaria Slovenia Croatia Bosnia-Herzegovina Yugoslavia Macedonia Moldova Albania Malta Cyprus Turkey Israel Belarus Ukraine Russia Georgia Armenia Kazakhstan Azerbaijan Kyrgyzstan Tajikistan Uzbekistan Turkmenistan